Study of AT-752 in Healthy Subjects in a Dengue Human Challenge Model

Atea Pharmaceuticals

Status and phase: Terminated; Phase 1

Conditions: Dengue

Treatments: Drug: AT-752; Drug: Placebo Comparator

Study type: Interventional

Funder types: Industry

Identifiers

NCT05366439

AT-02A-003

Details and patient eligibility

About

This study will assess the safety and antiviral activity of AT-752 in healthy subjects in a Dengue Human Challenge Model

Full description

A Phase 1, double-blind, randomized, placebo-controlled study to assess the antiviral activity and safety of AT-752 in a Dengue Human Challenge Model

Enrollment: 5 patients

Sex: All

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Must agree to use protocol-specified methods of contraception
• Negative pregnancy test
• Willing to comply with the study requirements and to provide written informed consent

Exclusion criteria

• Pregnant or breastfeeding
• Abuse of drugs
• Other clinically significant medical conditions

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

5 participants in 2 patient groups, including a placebo group

AT-752

Experimental group

Description:

AT-752 administered orally for 14 days

Treatment:

Drug: AT-752

Placebo

Placebo Comparator group

Description:

Matching placebo administered orally for 14 days

Treatment:

Drug: Placebo Comparator